Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

3SBio In-licenses Cancer Drug from Alteogen

publication date: Oct 13, 2015
3SBio, a China biopharma based in Shenyang, entered into an exclusive licensing deal with South Korea's Alteogen for the development, manufacturing and marketing of ALT-P7 in the territory of Mainland China, Hong Kong and Macau. ALT-P7 is a novel antibody-drug conjugate (ADC) targeting HER2 pathway for treating HER2-positive cancers, and currently in preclinical development. Alteogen will receive upfront, milestones and royalty payments from 3SBio. Further financial details were not disclosed. More details....

Stock Symbol: (HK: 1530) (KS: 196170)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital